Elixirgen Therapeutics, Inc. logo

Elixirgen Therapeutics, Inc.

Reimagine the Power of RNA

13 employees · est. 2017 · Baltimore, United States

VS
Biosplice Therapeutics logo

Biosplice Therapeutics

Restore health by delivering first-in-class therapies that harness alternative splicing

37 employees · est. 2008 · San Diego, United States

Biosplice Therapeutics is the older company (2017 vs 2008).

Side-by-Side Comparison

Elixirgen Therapeutics, Inc. Biosplice Therapeutics
Founded
2017 2008 older
Headquarters
Baltimore, United States San Diego, United States
Employees
13 37
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Life Sciences
Funding Stage
Series Unknown Grant
Total Funding
$25.91M $778.00M
Funding Rounds
5 6
Services
Not tracked yet Therapeutic Modulation of Alternative Splicing
Target Customers
Not tracked yet Patients with Osteoarthritis, Cancer, Neurological Disorders, and Diabetes
Taxonomy
RNA Therapeutics, MRNA Technology, Cell And Gene Therapies, Rare And Genetic Diseases, Aging-related Disorders, Duchenne Muscular Dystrophy, C-srRNA™ Technology, Telomere Biology Disorders, Stem Cell Biology, Regenerative Medicine, Johns Hopkins Science + Technology Park, Biotechnology Company, Intellectual Property, Drug Development, Clinical-stage Medical Research, Therapeutics Development, Regenerative Medicine, Oncology, Degenerative Diseases, Alternative Splicing, Wnt Pathway Modulation, Small Molecule Therapeutics, Clinical Development, Tissue-Level Regeneration, Alzheimer's Disease, Pre-mRNA Splicing, CLK/DYRK Kinases, Regenerative Pathways
Website
elixirgentx.com biosplice.com
Elixirgen Therapeutics, Inc. logo

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a biotechnology startup that is making significant strides in the field of RNA therapeutics. The company's focus lies in developing innovative therapies, including cell and gene therapies, to address a wide range of diseases such as rare and genetic disorders, as well...

Biosplice Therapeutics logo

About Biosplice Therapeutics

Biosplice Therapeutics, founded in 2008 and headquartered in the United States, is dedicated to restoring health by delivering pioneering therapies that leverage alternative splicing. The company's focus on small-molecule therapeutics, rooted in the groundbreaking science of alternative pre-mRNA spl...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Elixirgen Therapeutics, Inc. and Biosplice Therapeutics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Elixirgen Therapeutics... and Biosplice Therapeutics — by email.

Frequently Asked Questions

Elixirgen Therapeutics, Inc. — Reimagine the Power of RNA. Biosplice Therapeutics — Restore health by delivering first-in-class therapies that harness alternative splicing. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Elixirgen Therapeutics, Inc. has raised $25.91M while Biosplice Therapeutics has raised $778.00M.
Elixirgen Therapeutics, Inc. and Biosplice Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Elixirgen Therapeutics, Inc. with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy